Chemomab’s Positive Trial Results Boost Investor Confidence

Chemomab Therapeutics (CMMB) has released an update.

Chemomab Therapeutics reported promising results from its Phase 2 SPRING trial for CM-101, a potential treatment for primary sclerosing cholangitis, driving investor interest and strategic partnership discussions. The company secured $10 million in private placement funding, extending its cash runway to early 2026. Chemomab plans to advance CM-101 to a Phase 3 trial in late 2025, aiming to further capitalize on its promising pipeline.

For further insights into CMMB stock, check out TipRanks’ Stock Analysis page.